ALZHEIMER’S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING

CHICAGO, Aug. 29, 2025 /PRNewswire/ — The Alzheimer’s Association welcomes today’s U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early Alzheimer’s disease. With this approval, Leqembi IQLIK is…